SITE003-0225

SITE003 (CAN) › SITE003-0225

SITE003-0225

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2026-05-23

enrolled

AEs

1

Serious

0

Dropout signal

–

Adverse events

1

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-03-06 (study day 95); relationship: NOT RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.